Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2975

1.

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).

Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF.

Gynecol Oncol Rep. 2020 Feb 3;32:100546. doi: 10.1016/j.gore.2020.100546. eCollection 2020 May.

2.

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.

Arend R, Westin SN, Coleman RL.

Int J Gynecol Cancer. 2020 Feb 19. pii: ijgc-2019-001041. doi: 10.1136/ijgc-2019-001041. [Epub ahead of print] Review.

PMID:
32079709
3.

A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.

Brady L, Gil da Costa RM, Coleman IM, Matson CK, Risk MC, Coleman RT, Nelson PS.

Prostate. 2020 Feb 18. doi: 10.1002/pros.23963. [Epub ahead of print]

PMID:
32068909
4.

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.

Rees M, Angioli R, Coleman RL, Glasspool R, Plotti F, Simoncini T, Terranova C.

Maturitas. 2020 Feb 11. pii: S0378-5122(20)30025-6. doi: 10.1016/j.maturitas.2020.01.005. [Epub ahead of print]

PMID:
32059825
5.

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. Reply.

Coleman RL.

N Engl J Med. 2020 Feb 13;382(7):686. doi: 10.1056/NEJMc1916477. No abstract available.

PMID:
32053314
6.

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.

Rees M, Angioli R, Coleman RL, Glasspool RM, Plotti F, Simoncini T, Terranova C.

Int J Gynecol Cancer. 2020 Feb 11. pii: ijgc-2020-001217. doi: 10.1136/ijgc-2020-001217. [Epub ahead of print]

PMID:
32046979
7.

Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients.

Goldman MD, Dwyer L, Coleman R, Sohn MW, Stuve O.

PLoS One. 2020 Feb 11;15(2):e0228617. doi: 10.1371/journal.pone.0228617. eCollection 2020.

8.

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.

Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN.

Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095-0. doi: 10.1016/j.ygyno.2020.01.042. [Epub ahead of print]

PMID:
32037195
9.

Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86).

Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR.

Lancet Diabetes Endocrinol. 2020 Mar;8(3):206-215. doi: 10.1016/S2213-8587(20)30003-6. Epub 2020 Feb 4.

PMID:
32032540
10.

A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients.

Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF 3rd, Madhavan S.

JAMIA Open. 2019 Oct 7;2(4):505-515. doi: 10.1093/jamiaopen/ooz045. eCollection 2019 Dec.

11.

Dynamic Assembly and Disassembly of the Human DNA Polymerase δ Holoenzyme on the Genome In Vivo.

Drosopoulos WC, Vierra DA, Kenworthy CA, Coleman RA, Schildkraut CL.

Cell Rep. 2020 Feb 4;30(5):1329-1341.e5. doi: 10.1016/j.celrep.2019.12.101.

12.

Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).

Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C.

Clin Breast Cancer. 2020 Jan 8. pii: S1526-8209(20)30004-5. doi: 10.1016/j.clbc.2020.01.001. [Epub ahead of print] Review.

13.

Low-grade serous ovarian cancer: State of the science.

Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM.

Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862-1. doi: 10.1016/j.ygyno.2019.12.033. [Epub ahead of print] Review.

PMID:
31969252
14.

Species Radiations in the Sea: What the Flock?

Bowen BW, Forsman ZH, Whitney JL, Faucci A, Hoban M, Canfield SJ, Johnston EC, Coleman RR, Copus JM, Vicente J, Toonen RJ.

J Hered. 2020 Feb 5;111(1):70-83. doi: 10.1093/jhered/esz075.

PMID:
31943081
15.

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.

Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I, Brown S.

Trials. 2020 Jan 15;21(1):89. doi: 10.1186/s13063-019-3643-6.

16.

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.

Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL.

Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873-6. doi: 10.1016/j.ygyno.2019.12.043. [Epub ahead of print]

PMID:
31924332
17.

European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.

Herzog TJ, Secord AA, Coleman RL, Naumann RW.

Gynecol Oncol. 2020 Feb;156(2):265-270. doi: 10.1016/j.ygyno.2019.11.010. Epub 2020 Jan 3.

PMID:
31911006
18.

Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].

Naumann RW, Coleman RL, Brown J, Moore KN.

Gynecol Oncol. 2020 Feb;156(2):512-513. doi: 10.1016/j.ygyno.2019.12.007. Epub 2019 Dec 16. No abstract available.

PMID:
31859001
19.

Clinical benefits of bone targeted agents in early breast cancer.

Coleman R.

Breast. 2019 Nov;48 Suppl 1:S92-S96. doi: 10.1016/S0960-9776(19)31133-6.

20.

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).

Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Cheung SYA, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW.

Clin Cancer Res. 2019 Dec 13. doi: 10.1158/1078-0432.CCR-19-3053. [Epub ahead of print]

21.

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.

Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, Jandial D, Chan A.

Lancet Oncol. 2020 Jan;21(1):60-72. doi: 10.1016/S1470-2045(19)30687-4. Epub 2019 Dec 2.

PMID:
31806543
22.

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.

Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL.

Clin Cancer Res. 2019 Dec 3. doi: 10.1158/1078-0432.CCR-19-2962. [Epub ahead of print]

23.

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.

Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL.

Int J Gynecol Cancer. 2020 Jan;30(1):89-93. doi: 10.1136/ijgc-2019-000714. Epub 2019 Dec 1.

PMID:
31792084
24.

Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.

Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK.

Sci Rep. 2019 Nov 26;9(1):17589. doi: 10.1038/s41598-019-53872-1.

25.

Emerging serine-threonine kinase inhibitors for treating ovarian cancer.

Maoz A, Ciccone MA, Matsuzaki S, Coleman RL, Matsuo K.

Expert Opin Emerg Drugs. 2019 Dec;24(4):239-253. doi: 10.1080/14728214.2019.1696773.

PMID:
31755325
26.

Campylobacter in an Urban Estuary: Public Health Insights from Occurrence, HeLa Cytotoxicity, and Caco-2 Attachment Cum Invasion.

Siddiqee MH, Henry R, Coleman RA, Deletic A, McCarthy DT.

Microbes Environ. 2019 Dec 27;34(4):436-445. doi: 10.1264/jsme2.ME19088. Epub 2019 Nov 16.

27.

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS.

N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626.

28.

Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial.

Walsh JS, Marshall H, Smith IL, Greenfield DM, Swain J, Best E, Ashton J, Brown JM, Huddart R, Coleman RE, Snowden JA, Ross RJ.

PLoS Med. 2019 Nov 12;16(11):e1002960. doi: 10.1371/journal.pmed.1002960. eCollection 2019 Nov.

29.

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.

Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN.

Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32783. [Epub ahead of print]

PMID:
31714586
30.

An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain.

Danson S, Mulvey MR, Turner L, Horsman J, Escott K, Coleman RE, Ahmedzai SH, Bennett MI, Andrew D.

J Bone Oncol. 2019 Sep 18;19:100261. doi: 10.1016/j.jbo.2019.100261. eCollection 2019 Dec.

31.

Clinical and biological significance of EZH2 expression in endometrial cancer.

Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK.

Cancer Biol Ther. 2020;21(2):147-156. doi: 10.1080/15384047.2019.1672455. Epub 2019 Oct 22.

PMID:
31640461
32.

Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.

Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL.

Clin Cancer Res. 2020 Feb 1;26(3):581-587. doi: 10.1158/1078-0432.CCR-19-0471. Epub 2019 Oct 18.

PMID:
31628143
33.

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C.

Gynecol Oncol. 2019 Dec;155(3):420-428. doi: 10.1016/j.ygyno.2019.09.024. Epub 2019 Oct 15.

PMID:
31623857
34.

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.

Coleman RL, Scott CAB, Lang Z, Bethel MA, Tuomilehto J, Holman RR.

Cardiovasc Diabetol. 2019 Oct 17;18(1):135. doi: 10.1186/s12933-019-0933-y.

35.

Metabolite Changes in an Estuarine Annelid Following Sublethal Exposure to a Mixture of Zinc and Boscalid.

Sinclair GM, O'Brien AL, Keough M, de Souza DP, Dayalan S, Kanojia K, Kouremenos K, Tull DL, Coleman RA, Jones OAH, Long SM.

Metabolites. 2019 Oct 15;9(10). pii: E229. doi: 10.3390/metabo9100229.

36.

Correction: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.

Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL.

J Exp Med. 2019 Oct 7;216(10):2448. doi: 10.1084/jem.2018076508222019c. No abstract available.

37.

Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.

Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT.

Am J Obstet Gynecol. 2019 Oct 3. pii: S0002-9378(19)31165-2. doi: 10.1016/j.ajog.2019.09.036. [Epub ahead of print]

PMID:
31586602
38.

Improving the quality of referrals to ambulatory emergency care.

Keaney K, Sweeney A, Visanji S, Hawksley A, Coleman R.

Future Healthc J. 2019 Jun;6(Suppl 2):7. doi: 10.7861/futurehosp.6-2s-s7. No abstract available.

39.

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.

N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.

40.

Diagnosis and treatment of cryptogenic organizing pneumonia in a child on ECMO.

Sayad E, Coleman RD, Silva-Carmona MD.

Pediatr Pulmonol. 2020 Jan;55(1):20-22. doi: 10.1002/ppul.24502. Epub 2019 Aug 30. No abstract available.

PMID:
31469247
41.

Correction: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer.

Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL.

J Exp Med. 2019 Aug 27. pii: jem.2018076508222019C. doi: 10.1084/jem.2018076508222019C. [Epub ahead of print] No abstract available.

PMID:
31455603
42.

OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.

Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M.

Gynecol Oncol. 2019 Oct;155(1):126-134. doi: 10.1016/j.ygyno.2019.08.009. Epub 2019 Aug 13.

PMID:
31416612
43.

The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers.

Lheureux S, Mirza M, Coleman R.

J Clin Oncol. 2019 Sep 20;37(27):2449-2459. doi: 10.1200/JCO.19.00347. Epub 2019 Aug 12. No abstract available.

PMID:
31403862
44.

Left Atrial Decompression on Venoarterial Extracorporeal Membrane Oxygenation: Getting to the Heart of the Matter.

Coleman RD, Chartan CA, Qureshi AM, Shekerdemian LS.

Pediatr Crit Care Med. 2019 Aug;20(8):780-781. doi: 10.1097/PCC.0000000000001956. No abstract available.

PMID:
31397811
45.

Salmonella from a Microtidal Estuary Are Capable of Invading Human Intestinal Cell Lines.

Siddiqee MH, Henry R, Deletic A, Bulach DM, Coleman RA, McCarthy DT.

Microb Ecol. 2020 Feb;79(2):259-270. doi: 10.1007/s00248-019-01419-2. Epub 2019 Aug 5.

PMID:
31384980
46.

Individual, social, and environmental factors affecting salivary and fecal cortisol levels in captive pied tamarins (Saguinus bicolor).

Price E, Coleman R, Ahsmann J, Glendewar G, Hunt J, Smith T, Wormell D.

Am J Primatol. 2019 Aug;81(8):e23033. doi: 10.1002/ajp.23033. Epub 2019 Aug 1.

PMID:
31368125
47.

Using metabolomics to assess the sub-lethal effects of zinc and boscalid on an estuarine polychaete worm over time.

Sinclair GM, O'Brien AL, Keough M, De Souza DP, Dayalan S, Kanojia K, Kouremenos K, Tull DL, Coleman RA, Jones OAH, Long SM.

Metabolomics. 2019 Jul 31;15(8):108. doi: 10.1007/s11306-019-1570-x.

PMID:
31367897
48.

Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?

Chelariu-Raicu A, Coleman RL, Sood AK.

Oncology (Williston Park). 2019 Jul 16;33(7). pii: 629378.

49.

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C.

J Clin Invest. 2019 Jul 30;130:4492-4505. doi: 10.1172/JCI128212.

50.

Enantiomeric 4'-Truncated 3-deaza-1',6'-isoneplanocins: Synthesis and antiviral properties including Ebola.

Liu C, Coleman R, Archer A, Hussein I, Bowlin TL, Chen Q, Schneller SW.

Bioorg Med Chem Lett. 2019 Sep 1;29(17):2480-2482. doi: 10.1016/j.bmcl.2019.07.021. Epub 2019 Jul 11.

PMID:
31358469

Supplemental Content

Loading ...
Support Center